483 Revance Therapeutics Jul 2021

483 Revance Therapeutics Jul 2021

Carla Lundi FDA, Joao Pedras Vasconcel FDA$119.00 - Available Now

FDA investigators audited the Revance Therapeutics - Newark, CA, United States facility and issued inspectional observations (via FDA 483) on 02 Jul 2021.

Product details

  • Category: Human Drugs
  • Inspection end: 02 Jul 2021
  • Location: Newark, United States
  • FEI: 3007772056
Add To Cart